TigaTx Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TigaTx Inc. - overview
Established
2024
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2024 by Chief Executive Officer Anne Altmeyer, TigaTx Inc. operates as a biotechnology company that provides research and antibodies that are intended to fight viral infections and cancer. In December 2024, TigaTx Inc. raised USD 35.
5 million in venture funding from the Advanced Research Projects Agency for Health and the National Institutes of Health. TigaTx, Inc. specializes in engineered immunoglobulin A (IgA) antibodies designed to function as neutrophil engagers in the fight against cancer. Its therapies focus on improving the body's immune response by harnessing the tumor-killing capabilities of neutrophils, a type of white blood cell essential for combating cancerous cells.
The company's product offerings target various cancers, addressing unmet medical needs by providing potential therapeutic solutions for patients. As of 2024, the firm focuses on serving markets in North America and Europe, to support hospitals, oncology clinics, and research institutions that cater to cancer patients and healthcare providers. The company plans to use the funding from December 2024 to expand the use of IgA in the treatment of infectious illnesses.
Current Investors
Epsilogen Ltd
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment
Website
www.tigatx.com
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.